Supplementary Figure S7 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

Figure S7. huAR9.6 mediates tumor burden reduction by targeting the MUC16-ErbB signaling axis and the apoptotic cascade. (A) IHC for pErbB3 (Y1289), pErbB2 (Y1248), pErbB1 (Y1173) and pAKT (S473) in subcutaneous tumor tissues obtained from mice treated with vehicle (PBS) and huAR9.6 (500 µg/25 g bodyweight, i.p.). Histoscore quantification of (B) pErbB3, (C) pErbB2, (D) pErbB1 and (E) pAKT staining. (F) IHC for pErbB3 (Y1289), pErbB2 (Y1248), pAKT (S473) in patient-derived organoids treated with vehicle (PBS), isotype control huIgG and huAR9.6 (40 µg/mL for 24 h). (G) IHC for cleaved caspase 3 in subcutaneous tumor tissues obtained from mice treated with vehicle (PBS) and huAR9.6 (500 µg/25 g bodyweight, i.p.) (n=5). (H) Histoscore quantification of cleaved caspase 3. Scale bar 50 µm. Mean ± SD, p < 0.05 was considered as statistically significant using the Student’s t-test.